there is a lower relapse rate, which can be attributed to a lack of graft tumor contamination and an immunologic graft-versus-tumor effect. In addition, the donor stem cell pool is healthy, having no prior exposure to chemotherapeutic agents. Therefore, since patients who fail ABMT have a dismal prognosis, the use of alloBMT may be justified as salvage therapy. In this report, we describe the outcome after alloBMT in a series of 23 children, all of whom had previously undergone ABMT.
Materials and methods

Patient details
We retrospectively analyzed the records of 310 consecutive children who underwent alloBMT between February 1992 and August 1999 at St Jude Children's Research Hospital and identified 23 patients who underwent alloBMT for recurrent malignancy, secondary leukemia, or graft failure following ABMT. The patient with graft failure was transplanted for persistent trilineage aplasia with no evidence of disease recurrence over 2 years post autograft. All patients had been treated on institutional protocols for AML or NHL approved by the Institutional Review Board (IRB). Patient details are shown in Table 1 . Neutrophil engraftment was defined as the first of 3 consecutive days on which the absolute neutrophil count (ANC) was greater than 0.5 ϫ 10 9 /l. RRT was scored using the National Cancer Institute (NCI) Common Toxicity Criteria.
Autologous transplant details
All patients were transplanted on IRB approved protocols. During this time period, all patients at our institution with AML (except AML M3) who lacked an HLA-identical sibling donor received induction chemotherapy followed by ABMT in first remission. Patients with recurrent NHL which was chemosensitive underwent ABMT. All patients had no detectable marrow disease at the time of stem cell collection. The stem cell source was bone marrow for all patients except one (UPN 551) who received peripheral blood stem cells. Bone marrow was harvested from bilateral posterior iliac crests to obtain more than 1.0 ϫ 10 8 nucleated cells/kg. Four patients (UPN 317, 425, 437, 580) received a bone marrow graft purged with 4-hydroxycyclo- phosphamide with or without interleukin-2 or monoclonal antibodies to CD15. 3 Peripheral blood stem cells were obtained by leukapheresis using a continuous flow cell separator (COBE-Spectra, COBE BCT, Lakewood, CO, USA) with 10-15 liters blood processed in each procedure. This procedure was performed once daily until the goal of 2 × 10 6 CD34 + cells/kg was obtained. Stem cell products were stored at −150°C using 10% dimethylsulfoxide (DMSO) and a controlled rate freeze program. All patients with acute leukemia were in remission and patients with NHL had chemosensitive disease at the time of ABMT. Patients with acute leukemia received busulfan (1 mg/kg, 16 doses) and cyclophosphamide (50 mg/kg, four doses) with Mesna uroprotection. 4 Patients with NHL received carboplatin (700 mg/m 2 , three doses) and etoposide (500 mg/m 2 , three doses). 5 Prior to reinfusion, the graft was rapidly thawed in a 37°C water bath at the bedside. One patient (UPN 425) received an infusion of autologous back-up marrow on day +35 due to poor engraftment.
Allogeneic transplant details
All patients were transplanted on IRB approved protocols. All patients in this report received the same conditioning regimen, graft manipulation and GVHD prophylaxis as patients with AML and NHL receiving a first transplant. Five patients received marrow from matched siblings, 14 from matched unrelated donors (matched at 5 or 6 HLA loci) and four from haploidentical family members. All patients received cytarabine (3 g/m 2 , six doses) and cyclophosphamide (45 mg/kg, two doses) with Mesna (45 mg/kg divided into five doses) administered before and 3, 6, 9, 12 h after each dose of cyclophosphamide. 6 They also received total body irradiation in eight fractions, for a total of 12 Gy (matched sibling marrow recipients) or 14 Gy (unrelated or mismatched family member marrow recipients). Antithymocyte globulin was administered as part of the pre-transplant conditioning regimen to 13 patients who received marrow from unrelated or mismatched family donors to enhance immunosuppression. Marrow from mismatched family members and from unrelated donors was depleted of approximately 1.5 logs T lymphocytes by use of anti-T cell monoclonal antibodies CD6 and CD8 plus rabbit complement. 6 Beginning 2 days before transplantation, all recipients received cyclosporin A, at a dosage adjusted to attain plasma levels of 200-350 ng/ml. Patients given matched sibling marrow received additional GVHD prophylaxis with pentoxyfylline or short-course methotrexate. Acute and chronic GvHD were graded according to standard criteria. 7 Patients with mild/moderate GvHD (grade 1 or 2) were treated with methylprednisolone (1-2 mg/kg daily). If GvHD remained at grade 2 for Ͼ7 days or progressed, the steroid dosage was increased to 5-10 mg/kg daily. One patient (UPN 317) who had no evidence of improvement after 5 days of high-dose steroid therapy was treated with CBL-1 monoclonal antibody, as previously described. 8 
Supportive care
Prophylaxis for Pneumocystis carinii pneumonia consisted of trimethroprim-sulfamethoxazole (co-trimoxazole) at 5 mg/kg daily divided into two doses, three times a week, in all patients with an ANC above 1.0 × 10 9 /l. Allograft recipients who were seropositive for CMV or had a CMV seropositive donor received ganciclovir (5 mg/kg twice daily) when the ANC exceeded 0.5 × 10 9 /l for 2 days. After 14 days the dose was reduced to 5 mg/day on 5 days per week until day 120 after transplantation. Intravenous immuno-globulin was given at 500 mg/kg weekly until day 120, then monthly thereafter until 12 months after allogeneic transplantation. Patients receiving T cell-depleted grafts were eligible to receive donor-derived cytotoxic T cells specific for Epstein-Barr virus as prophylaxis against Epstein-Barr virus lymphoproliferative disease. 9 No preventive treatment for fungal infections or VOD was provided.
Statistics
Survival was defined as the time interval from second BMT to death from any cause. For DFS, an event was defined as relapse (hematologic, CNS, or extramedullary), evidence of disease progression, or death due to any cause. The date of first event was used in calculating DFS. For these survival analyses, time was censored at the last follow-up date if no failure was observed. Life table estimates of the probability of DFS was derived by the method of KaplanMeier 10 and were compared using the exact log rank test. Time-to-event measures were calculated from the day of alloBMT. Regimen-related mortality included deaths due to any cause other than disease. In the analysis of calculating cumulative incidence of treatment-related mortality after second transplant, death caused by disease was considered as competing risk. Death from any cause without relapse was considered as competing risk for calculating cumulative incidence of relapse after the second transplant. The cumulative incidence was estimated using the method described by Pentice et al.
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Results
Patient characteristics
Demographic data for the 23 patients are outlined in Table  1 . Twenty had an initial diagnosis of de novo AML; one patient developed secondary AML following therapy for ALL (UPN 238). In two patients, the malignancy was large cell NHL. One with immunoblastic histology was autografted in second remission, but allografted in fourth remission; the other had anaplastic histology and underwent ABMT in second remission and allograft in second chemosensitive relapse. All but one patient underwent alloBMT for recurrent disease. One patient (UPN 425) with AML had poor graft function following ABMT despite infusion of back-up marrow. The median time to disease recurrence after ABMT was 161 days (range, 48-918 days) ( Table 2 ). The median time from the ABMT to alloBMT was 291 days (range, 72-1460 days) ( Table 3) .
Induction therapy prior to allogeneic BMT
The median time from disease recurrence to allograft was 93 days (range, 17-542 days) ( Table 3) . Fourteen had received prior induction chemotherapy and five were in complete remission at the time of alloBMT. Nine patients went immediately to alloBMT. 
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Allogeneic transplant outcome
Twenty-two patients engrafted achieving an ANC of 0.5 ϫ 10 9 /l at a median of day +19 (range, 14-36 days); one patient died prior to engraftment. Eight developed grade II-IV acute GVHD; of these, only four patients had grade III-IV acute GVHD. Only four of 17 patients evaluable developed chronic GVHD; three of these patients had limited chronic GVHD. One developed extensive chronic GVHD. Eight patients died of RRT (Table 3) , two of whom had recurrent disease. Four died of pneumonitis or diffuse alveolar hemorrhage (DAH), one of GVHD, one of post transplant EBV lymphoma, one of encephalitis, and one of toxic epidermal necrolysis. The cumulative incidence of regimen-related mortality is 34.8% at 2 years ( Figure 1 ). Although there was also a high incidence of other grade III-IV toxicity in this heavily pretreated population (Table  3) , five patients had no grade III-IV non-hematologic toxicity. Eight patients relapsed at a median of 206 days (range, 35-669 days) post alloBMT and although some received further chemotherapy or donor lymphocyte infusions, all but two (one died from pulmonary failure and the other DAH) eventually died of disease. Patients with acute or chronic GVHD did not have a significantly different relapse rate than patients who did not have these complications (40% vs 31%, P = NS). Nine patients are alive disease-free between 627 and 2433 days post alloBMT resulting in a 4-year DFS of 39% ( Figure 2 ). All have maintained longer remissions than following their ABMT. The cumulative incidence of relapse is 35% at 3 years ( Figure  3 ). All nine survivors currently have Karnofsky or Lansky scores of 90-100. CCR = continuous complete remission; ARDS = adult respiratory distress syndrome; DAH = diffuse alveolar hemorrhage; TEN = toxic epidermal necrolysis; VOD = veno-occlusive disease of the liver; TTP = thrombotic thrombocytopenic purpura; NE = not evaluable; NA = not applicable.
Risk factors for disease-free survival
An analysis to identify risk factors associated with DFS was performed. These risk factors included patient age, gender and race; use of pre-alloBMT chemotherapy, time from ABMT to alloBMT, disease status at alloBMT, history of prior fungal infection, pre-alloBMT pulmonary function test results (D L CO, FVC, FEV 1 , TLC), and prealloBMT liver function studies (SGOT, SGPT, LDH). While there was a trend for improved DFS among patients who did not receive chemotherapy prior to alloBMT (56% vs 29%, P = NS), it did not reach statistical significance. No statistically significant relationship was observed between any variable and DFS (data not shown).
Discussion
Patients with recurrent AML or NHL following ABMT have a poor prognosis. [12] [13] [14] Although some patients can attain remission with chemotherapy, these remissions are usually brief and there are few long-term survivors. In addition, patients who undergo second autologous or allogeneic stem cell transplants are at increased risk for RRT. [13] [14] [15] [16] [17] [18] [19] [20] However, allogeneic transplantation offers several advantages over ABMT: a healthy stem cell source, no risk of contamination by malignancy, and an immunologic graft-versus-malignancy effect. Therefore, the use of allografts for patients failing ABMT may be beneficial. Results of several recent analyses are shown in Table 4 . The largest published series describes the outcomes of 42 adults and 17 children undergoing alloBMT after a prior autograft. 21 Grafts were obtained from HLA-matched relatives (n = 14), mismatched relatives (n = 25), or unrelated donors (n = 20). Grafts were not depleted of T lymphocytes. This group reported that at 2 years the regimen-related mortality was 51%, the relapse rate was 26%, and DFS was 23%. Prolonged DFS was associated with age less than 17 years at transplant, remission at time of transplant, use of TBI-containing preparative regimen for alloBMT, and a diagnosis of AML. Acute GVHD was found to be associated with a decreased relapse risk. As in our study, no NHL patients survived.
A multi-center study of 20 adults with NHL and AML failing ABMT reported that 17 died at a median of 2 months after alloBMT, all from RRT. 16 Of the 18 evaluable reported that four of seven patients who underwent unrelated donor BMT for recurrent disease or graft failure after ABMT were alive disease-free. All developed grade I acute GVHD; the three deaths were due to RRT. In a third report, three of seven patients who had failed ABMT and subsequently received an allograft from a partially matched related donor were alive without disease at a median follow-up of 354 days. 18 As in our series, the authors found that the incidence of grade II-IV acute GVHD in patients receiving a second BMT was significantly higher than that observed in patients receiving a first BMT from a partially matched family member (43% vs 13%). Although followup is short, no patient developed recurrent disease. These three accounts describe low disease recurrence rates, suggesting an advantage to the use of allo-reactive donor grafts. However, our study did not confirm this observation, possibly due to the relatively low incidence of GVHD in our patient population or due to high regimen-related mortality. However, in all studies, RRT was a significant cause of mortality in this heavily pretreated patient population.
In a retrospective analysis of 168 patients with acute leukemia undergoing either allogeneic or ABMT after failing a prior ABMT, the European Group for Blood and Marrow Transplantation reported a 2-year leukemia-free survival (LFS) of 27% and 35%, respectively. 22 Transplant-related mortality was 51% and 26%, for patients receiving an allograft and autograft, respectively. The most common cause of death was recurrent disease among autograft recipients; regimen-related mortality was more common among allograft recipients. In a multivariate analysis, LFS was significantly decreased in patients older than 25 years of age, if the interval from autograft to relapse was 8 months or less, and if TBI was used at first autograft.
More recently, Blau et al 23 published the results of 27 patients with recurrent leukemia undergoing a second transplant from a related or unrelated donor after a prior allograft (n = 11) or ABMT (n = 16). Seven died of RRT and 12 of relapse. Eight survive (seven auto, one allo) with an overall DFS of 30%. Patients who had received a prior ABMT had a DFS of 43%. While both relapse and RRT were equally important causes of mortality, the DFS of the pediatric patients in our study compared favorably with that in other series. As in other studies of second transplants, 14, 18, 24 the incidence of grade II-IV acute GVHD (36.4%) was increased compared to patients undergoing first allograft at our institution, 6 where patients receiving first allografts from an HLA-identical sibling or from an unrelated donor had an incidence of grade II-IV GVHD of 15% and 22%, respectively. Other investigators have supposed that the increased GVHD is due to host tissue damage from the conditioning regimen resulting in increased HLA expression and release of inflammatory cytokines. 25 Although not observed in our study, GVHD may result in a graft-versus-malignancy effect, reducing relapse rates if toxicity from GVHD is not excessive. However, despite the increased incidence of acute GVHD, the incidence of grade II-IV GVHD was relatively low and recurrent disease seemed to be more frequent in our series compared to other studies. This observation may be attributed to several fac- tors. Most likely, the lower incidence of regimen-related mortality compared to other studies allowed patients to survive to be at risk of disease recurrence. Alternatively, these patients had been treated on aggressive therapeutic protocols with prior high-dose chemotherapy and ABMT, resulting in an increased risk of developing chemo-resistant disease. In fact, only five were in remission at the time of alloBMT. In addition, our patients recurred more rapidly after ABMT and proceeded more quickly to alloBMT compared to other series (Table 4 ). This latter observation may also have contributed to an increased RRT. 26 In addition, while the GHVD rate observed in patients receiving second allografts was higher than in patients receiving their first allograft, it was still lower than that reported in other series of allografting after ABMT. Since the majority of patients received their second transplant from an unrelated or mismatched related donor, the graft was depleted of T lymphocytes, which is associated with a higher relapse rate. 27 However, this observation was not confirmed in our series.
A high RRT rate, particularly VOD and pneumonitis, is probably a consequence of the combination of initial therapy for the malignancy, the induction therapy for the recurrent disease, and the transplant conditioning regimen. Risk factors for development of VOD and pneumonitis have been identified, suggesting that heavily pretreated patients are more likely to develop these complications. Risk factors for severe VOD include prior VOD following chemotherapy or hepatic irradiation, second stem cell transplant, pre-existing hepatitis with elevated transaminases, or extensive liver fibrosis or cirrhosis. [28] [29] Patients in our series had only one of these risk factors. Risk factors for idiopathic pneumonitis appear to be predominantly related to the conditioning regimen, with higher total doses and dose rates of TBI increasing the risk. [30] [31] [32] [33] In our series, patients received fractionated TBI to reduce this risk. None of our patients had received TBI for their first transplant and none were over 25 years at the time of alloBMT, both known risk factors for toxicity in patients undergoing second transplant. 22 In addition, certain chemotherapeutic agents (busulfan, BCNU, cytarabine, methotrexate) as well as prior pulmonary radiation can increase the risk. Several prophylaxis regimens have been studied to prevent these complications with varying levels of success. [34] [35] [36] [37] [38] [39] [40] [41] [42] The role of chemotherapy prior to a second transplant has not been clearly defined. While proceeding directly to transplant avoids additional organ toxicity caused by chemotherapy and spares the patient infection risks, some patients need time to obtain a donor and require chemotherapy to achieve disease control. In our series, the 4-year DFS was 29% for patients who received chemotherapy compared with 56% who did not receive chemotherapy (data not shown); however, this difference did not achieve statistical significance.
As the numbers of autologous HSCT increase, the need for subsequent allografts for patients with recurrent disease or treatment-related malignancies will probably increase. Presently, ABMT remains a curative option for patients with AML who lack a suitable allogeneic donor, with studies of ABMT and conventional chemotherapy showing that ABMT is superior to or equivalent to conventional chemotherapy. [43] [44] [45] [46] No study has demonstrated that outcomes with conventional chemotherapy are superior to ABMT. Autologous HSCT is still considered the primary salvage therapy for patients for recurrent NHL, particularly those with chemosensitive disease, and is being expanded in clinical trials to include high-risk patients in first remission. 47 In addition, ABMT is an alternative for patients who are not candidates for allogeneic HSCT for reasons such as lack of available donor, prior organ toxicity, prior infections, or age. Finally, autologous HSCT can be utilized to investi-gate novel methods of graft purging, gene therapy, and post transplant immunomodulation.
The results in our report are comparable to those in other series describing patients undergoing alloBMT after failing a prior autograft, with RRT and relapse reported to be significant causes of treatment failure.
In view of current results with traditional BMT regimens, alternative therapies are needed to reduce both relapse and non-relapse morbidity and mortality. Intensification of conditioning regimens is not an ideal option in this heavily pretreated group. Another option may be the addition of monoclonal antibodies reactive to host hematopoietic cells as part of a conditioning regimen to reduce residual leukemia. 48 One other solution to the problem of RRT would be to evaluate the role of immunosuppressive, subablative conditioning, with or without donor lymphocyte infusions post transplant. [49] [50] [51] [52] Several investigators have reported durable remissions in patients with hematologic and lymphoid malignancies who would not qualify for standard myeloablation. While RRT seems lower than anticipated for this high-risk patient population, GVHD remains a significant problem. In addition, recent data suggests graft-versusmalignancy effect may reduce relapse in some patients, justifying exploration of immunotherapy approaches post transplant. Therefore, patients requiring a second transplant may benefit from nonmyeloablative regimens with post transplant immunotherapy. 53 Finally, recent studies in ALL patients receiving standard chemotherapy have focused on pharmacogenetics, which studies the effect of genetic polymorphisms in drug metabolizing enzymes and how this may lead to inherited differences in drug effects. 54, 55 In addition, certain cytokine polymorphisms have been associated with early death and severe acute GVHD in recipients of HLA-identical sibling grafts. 56 These observations suggest that identification of individuals with a genetic predisposition towards toxicities could allow physicians to tailor pre-transplant chemotherapy regimens and/or conditioning regimens to minimize non-relapse mortality.
